Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN®-Filo Ebola vaccine regimen: a phase 2 randomised clinical study in Europe (EBOVAC2) (Lancet Infectious Diseases, 2020)

(untitled) - Pollard, AJ; Launey, O; Lelievre, J-D; Lacabaratz, C; Gibani, M; Clutterbuck, E